Lyra Q4 2020 Earnings Report
Key Takeaways
Lyra Therapeutics announced positive topline data from their LANTERN Phase 2 Study for LYR-210 and strengthened their team with the additions of Dr. Kern to the management team and Dr. Snyderman to the board. Cash and cash equivalents were $74.6 million as of December 31, 2020.
Announced positive topline results for LANTERN Phase 2 Study of LYR-210.
LYR-210 is the first nasal implant to achieve a benefit of up to six months after a single administration in a clinical testing, and the first nasal implant to achieve a benefit in both polyp and non-polyp patients in clinical testing.
Appointed Robert Kern, MD, Chief Medical Officer.
Added Nancy L. Snyderman, M.D. to Board of Directors.
Lyra
Lyra
Forward Guidance
Lyra has sufficient cash to fund the company through planned operations into 2023.